0001735276-23-000079.txt : 20230807
0001735276-23-000079.hdr.sgml : 20230807
20230807180545
ACCESSION NUMBER: 0001735276-23-000079
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230803
FILED AS OF DATE: 20230807
DATE AS OF CHANGE: 20230807
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Garg Pushkal
CENTRAL INDEX KEY: 0001829252
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36407
FILM NUMBER: 231148800
MAIL ADDRESS:
STREET 1: C/O SQZ BIOTECHNOLOGIES COMPANY
STREET 2: 200 ARSENAL YARDS BOULEVARD, SUITE 210
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001178670
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770602661
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 675 WEST KENDALL STREET
STREET 2: HENRI A. TERMEER SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 551-8200
MAIL ADDRESS:
STREET 1: 675 WEST KENDALL STREET
STREET 2: HENRI A. TERMEER SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020724
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2023-08-03
0
0001178670
ALNYLAM PHARMACEUTICALS, INC.
ALNY
0001829252
Garg Pushkal
675 WEST KENDALL STREET
HENRI A. TERMEER SQUARE
CAMBRIDGE
MA
02142
0
1
0
0
CMO & EVP Dev & Med Affairs
0
Common Stock
2023-08-03
4
A
0
4518
0.0
A
8863
D
Common Stock
2023-08-03
4
A
0
3109
0.0
A
11972
D
Common Stock
2023-08-04
4
S
0
658
184.7
D
11314
D
Common Stock
2023-08-04
4
S
0
1593
185.54
D
9721
D
Common Stock
2023-08-04
4
S
0
945
186.39
D
8776
D
Common Stock
2023-08-04
4
S
0
86
187.37
D
8690
D
Common Stock
2023-08-04
4
S
0
15
188.4
D
8675
D
Common Stock
2023-08-04
4
S
0
164
189.31
D
8511
D
Common Stock
2023-08-07
4
S
0
3112
183.58
D
5399
D
Common Stock
2023-08-07
4
S
0
814
184.65
D
4585
D
Common Stock
2023-08-07
4
S
0
240
185.32
D
4345
D
Common Stock
431
I
by Managed Account
Common Stock
250
I
by Trust
On February 26, 2020, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2019 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company.
On February 24, 2021, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2020 year-end compensation review. The PSUs vest in separate installments based on the achievement of four specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-quarter of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company.
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $184.01 to $185.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $185.02 to $186.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $186.03 to $187.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $187.04 to $188.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $188.14 to $189.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $183.09 to $184.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $184.12 to $184.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $185.20 to $185.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
Represents shares held in trust, of which the reporting persons spouse is co-trustee. The reporting person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
By: Stephen Hall, Attorney-in-Fact For: Pushkal Garg
2023-08-07